Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations

Lung cancer is a leading cause of cancer-related deaths worldwide [1]. However, in recent decades, the elucidation of key molecular mechanisms contributed to the improvement of prognosis in patients with lung cancer, especially in those with non-small cell lung cancer (NSCLC) [2]. In 2004, an association between somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) gene and the response to EGFR tyrosine kinase inhibitor (TKI) treatment were reported by several groups [3,4].

Source: Lung Cancer - November 29, 2018 Category: Cancer & Oncology Authors: Hanako Hasegawa, Hiroyuki Yasuda, Junko Hamamoto, Keita Masuzawa, Tetsuo Tani, Shigenari Nukaga, Toshiyuki Hirano, Keigo Kobayashi, Tadashi Manabe, Hideki Terai, Shinnosuke Ikemura, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima Source Type: research